217 related articles for article (PubMed ID: 35884581)
1. HER2-Targeted Antibody-Drug Conjugates Display Potent Antitumor Activities in Preclinical Extramammary Paget's Disease Models: In Vivo and Immunohistochemical Analyses.
Tokuchi K; Maeda T; Kitamura S; Yanagi T; Ujiie H
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884581
[TBL] [Abstract][Full Text] [Related]
2. Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies.
Maeda T; Kitamura S; Nishihara H; Yanagi T
Oncogene; 2020 Sep; 39(36):5867-5875. PubMed ID: 32724160
[TBL] [Abstract][Full Text] [Related]
3. Extramammary Paget's Disease in Two Brothers.
Zhang X; Jin W; Zhu H; Yu H
Indian J Dermatol; 2015; 60(4):423. PubMed ID: 26288451
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase 4/6 inhibitors suppress tumor growth in extramammary Paget's disease.
Kitamura S; Yanagi T; Maeda T; Ujiie H
Cancer Sci; 2022 Feb; 113(2):802-807. PubMed ID: 34866279
[TBL] [Abstract][Full Text] [Related]
5. A Case of Metastatic Extramammary Paget's Disease Responding to Trastuzumab plus Paclitaxel Combination Therapy.
Hanawa F; Inozume T; Harada K; Kawamura T; Shibagaki N; Shimada S
Case Rep Dermatol; 2011 Sep; 3(3):223-7. PubMed ID: 22135629
[TBL] [Abstract][Full Text] [Related]
6. Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget's disease (EMPD-HER2DOC).
Hirai I; Tanese K; Nakamura Y; Fukuda K; Ouchi T; Hayashida T; Kameyama K; Abe T; Amagai M; Funakoshi T
Oncologist; 2024 Jun; ():. PubMed ID: 38823035
[TBL] [Abstract][Full Text] [Related]
7. Human epidermal growth factor receptor 2 amplification as a biomarker for treatment in patients with lymph node-metastatic penoscrotal extramammary Paget's disease.
Lu X; Zhang P; Zhu Y; Ye D
Oncol Lett; 2019 Mar; 17(3):2677-2686. PubMed ID: 30854041
[TBL] [Abstract][Full Text] [Related]
8. Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature.
Barth P; Dulaimi Al-Saleem E; Edwards KW; Millis SZ; Wong YN; Geynisman DM
Case Rep Oncol Med; 2015; 2015():895151. PubMed ID: 25692060
[TBL] [Abstract][Full Text] [Related]
9. Successful and long-term response to trastuzumab plus paclitaxel combination therapy in human epidermal growth factor receptor 2-positive extramammary Paget's disease: A case report and review of the literature.
Ichiyama T; Gomi D; Fukushima T; Kobayashi T; Sekiguchi N; Sakamoto A; Sasaki S; Mamiya K; Koizumi T; Hama Y
Mol Clin Oncol; 2017 Nov; 7(5):763-766. PubMed ID: 29181166
[TBL] [Abstract][Full Text] [Related]
10. Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy.
Takahagi S; Noda H; Kamegashira A; Madokoro N; Hori I; Shindo H; Mihara S; Hide M
J Dermatol; 2009 Aug; 36(8):457-61. PubMed ID: 19691751
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin.
Zattarin E; Nichetti F; Ligorio F; Mazzeo L; Lobefaro R; Fucà G; Peverelli G; Vingiani A; Bianchi GV; Capri G; de Braud F; Vernieri C
Front Oncol; 2022; 12():925551. PubMed ID: 36059635
[TBL] [Abstract][Full Text] [Related]
12. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
14. NECTIN4-targeted antibody-drug conjugate is a potential therapeutic option for extramammary Paget disease.
Tanaka Y; Ito T; Murata M; Tanegashima K; Kaku-Ito Y; Nakahara T
Exp Dermatol; 2024 Mar; 33(3):e15049. PubMed ID: 38509717
[TBL] [Abstract][Full Text] [Related]
15. Novel ex vivo disease model for extramammary Paget's disease using the cancer tissue-originated spheroid method.
Arita T; Kondo J; Kaneko Y; Tsutsumi M; Kanemaru M; Matsui M; Arakawa Y; Katoh N; Inoue M; Asai J
J Dermatol Sci; 2020 Sep; 99(3):185-192. PubMed ID: 32800410
[TBL] [Abstract][Full Text] [Related]
16. Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.
Mukohara T; Hosono A; Mimaki S; Nakayama A; Kusuhara S; Funasaka C; Nakao T; Fukasawa Y; Kondoh C; Harano K; Naito Y; Matsubara N; Tsuchihara K; Kuwata T
Oncologist; 2021 Aug; 26(8):635-639. PubMed ID: 33559918
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the methods used to detect HER2-positive advanced extramammary Paget's disease.
Hirai I; Tanese K; Nakamura Y; Otsuka A; Fujisawa Y; Yamamoto Y; Hata H; Fujimura T; Matsushita S; Yoshino K; Kameyama K; Amagai M; Funakoshi T
Med Oncol; 2018 May; 35(6):92. PubMed ID: 29744813
[TBL] [Abstract][Full Text] [Related]
18. KS-EMPD-1: a novel cell line of primary extramammary Paget's disease.
Ito T; Tanaka Y; Ichiki T; Kaku-Ito Y; Nakahara T
Hum Cell; 2023 Sep; 36(5):1813-1829. PubMed ID: 37432591
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease.
Gatalica Z; Vranic S; Krušlin B; Poorman K; Stafford P; Kacerovska D; Senarathne W; Florento E; Contreras E; Leary A; Choi A; In GK
Cancer Med; 2020 Feb; 9(4):1441-1450. PubMed ID: 31899853
[TBL] [Abstract][Full Text] [Related]
20. Extramammary Paget's disease: Updates in the workup and management.
Nabavizadeh R; Vashi KB; Nabavizadeh B; Narayan VM; Master VA
Asian J Urol; 2022 Oct; 9(4):451-459. PubMed ID: 36381596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
